Deanxit: Formula, Presentation, Indications, Dosage, Side Effects Warnings and Interactions

It is considered a drug capable of alleviating the symptoms of depressed mood.

Deantix combines two ingredients, the active ingredients of flupenthixol (0.5mg), which has antipsychotic, and melitracen (10mg) effects, a tricyclic antidepressant.

Both make up a preparation that, when mixed, works, maximizing the effect against the disease.

Combining these two active ingredients gives them antidepressant, anxiolytic and stimulating properties.

Chemical formula

  • Diclorhidrato de Flupentixol C23H25F3N2OS.
  • Melithracene Hydrochloride C21H25N.

Presentation of Deanxit

Pink, round and biconvex tablets of 10 / 0.5 mg.


Deanxit is prescribed to treat mild and moderate anxiety and depression in patients with or without psychosomatic symptoms.

Mechanism of action

The mechanism of action of tricyclic antidepressants is still uncertain.

It was always thought that tricyclic antidepressants inhibit the reuptake of amines (dopamine, norepinephrine, and serotonin), improving neurotransmission.

Although the biochemical activity of antidepressants is started as soon as it is administered, their therapeutic effect does not appear until after 2 to 4 weeks of treatment have elapsed.

Dosage of Deanxit

A dragee should be administered in the morning and at noon for the first three days in the first dose.

One or two tablets should be administered in the usual dose, one in the morning and another at noon.

If necessary, a third dose should be added to prevent sleep disturbance, so it should be administered before 6 in the evening.

It is sufficient to administer only one tablet a day in the morning in geriatric patients.

Suspend treatment, it must be done gradually and under medical supervision.

It is common for patients to respond to Deanxit treatment quickly.

Although if the maximum dose has been administered for a week without significant changes, suspension of treatment is likely recommended.

Side effects

Like most medications, the administration of Deanxit can cause adverse effects, although they do not occur in all patients.

Side effects are rare and of low intensity, usually solved with continued treatment.

But when the side effects are very intense or have a duration greater than days, you should inform the doctor.

The most frequent side effects may include dizziness and tremors.

Blurred vision can be presented with great difficulty in reading small letters.

It has also been reported difficulty in falling asleep, symptoms such as restlessness, agitation, dry mouth, constipation, fatigue, and weight gain.

There are also rare side effects which may include:

The presence of suicidal ideas or suicidal behavior, blood clots in the veins and particularly in the legs, and symptoms include swelling, pain, and redness in the legs.

The clots can move through the bloodstream until they can reach the lungs and, in turn, cause severe pain in the chest and difficulty breathing.

If these symptoms are observed, the doctor should be consulted immediately.

In geriatric patients with dementia, a slight increase in the number of deaths has been reported in the comparative studies of patients administered antipsychotics with those who do not.

Warnings and contraindications of Deanxit

Deanxit should not be administered in those cases that present:

Hypersensitivity to the drug components (allergy) to flupenthixol, melitracene, or any other members of Deanxit.

In case of having suffered from a heart attack (myocardial infarction) in recent times.

In case of having suffered from alterations of the heart’s normal rhythm, which can be observed in an electrocardiogram.

Monoamine oxidase inhibitors include phenelzine, iproniazide, isocarboxazide, nialamide, tranylcypromine, and moclobemide, which are also indicated for the treatment of depressive states.

Although the treatment of any of the following monoamine oxidase inhibitors has been suspended, it is advisable to wait two weeks before starting to take Deanxit, in the case of phenelzine, iproniazide, isocarboxazide, nialamide, and tranylcypromine.

And it must have been at least a day since the moclobemide was stopped.

Deanxit in tablets is contraindicated in patients with severe depression.

Also, for patients who must remain with treatments in hospitals or it is necessary, electro-convulsive therapy for its treatment, as well as it should not be administered in patients with excitable or hyperactive behaviors.

Special care must be taken with the administration of Deanxit when the following pathologies have been presented:

  • If the patient suffers from some disorder in the liver.
  • If the patient has a history of attacks or seizures.
  • If the patient has diabetes, and if necessary, they will probably need an adjustment of the antidiabetic treatment.
  • If the patient suffers from an organic brain syndrome or a mental disorder that results from alcohol intoxication or organic solvents.
  • If a patient or someone in your family has a history of clot formation in the blood due to the risk of administering this drug since it has been linked to blood clots.
  • In children and adolescents, Deanxit can not be used to treat depression for this age group.

In studies that have been conducted on the application of treatment for depression performed in this age group, tricyclic antidepressants have not shown favorable effects.

Because a more significant occurrence of suicide attempts has been observed, some suicidal ideas, particularly hostility, predominance in symptoms of aggression, aggressive behavior, and irritation.

Likewise, it has been reported that the administration of Deanxit in these age groups leads to an increased risk of the appearance of adverse effects related to the cardiovascular system.

The risk of suicide is associated with psychiatric disorders and suicidal thoughts common in patients with depressive symptoms.

These risks often persist until the antidepressant effect of the treatment is present in the patient.

If the patient is in a depressive state and suffers from an anxiety disorder, he may sometimes have thoughts that incite him to harm himself or induce him to commit suicide.

These behaviors increase when taking antidepressants for the first time since these drugs require a time to start their effects, usually about two weeks, although in some cases, they could take a longer time.

The patient is more likely to present this type of thought when:

  • Previously he has shown this type of thought.
  • The patient is a young adult under 25 with psychiatric illness who has already been treated with antidepressants.

As for episodes of mania, it has been reported that some patients who have bipolar disorders that can enter this phase.

Which is characterized by the individual having frequent changes of ideas, exaggerated joys, and excessive physical activity.

It is essential to consult your doctor in these cases, as it is very likely to change treatment.


Some types of medication can affect the action of other drugs and, in some cases, can cause severe antagonistic reactions.

Particular caution should be used when prescribing Deanxit in combination with the following medications:

  • Other tricyclic antidepressants.
  • Lithium for the case prevention and treatment of bipolar disorders.
  • It should not be given simultaneously as ephedrine, isoprenaline, phenylephrine, noradrenaline, phenylpropanolamine, and some medicines to fight the cold.
  • Anticholinergic drugs such as atropine and hyoscyamine.
  • The medications that are used to reduce blood pressure.
  • Those medications cause drowsiness.
  • The medicines used for the treatment of epilepsy.
  • Levodopa is the drug used for the treatment of Parkinson’s disease.
  • Metoclopramide is used in the treatment of intestinal disorders.
  • Piperazine is one of the treatments that have been used for the treatment of intestinal worm infections.
  • If the patient should undergo surgery or dental treatment that requires local or general anesthesia, you should inform the doctor who is in therapy with Deanxit.